Welcome to our dedicated page for Henry Schein SEC filings (Ticker: HSIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Henry Schein, Inc. (NASDAQ: HSIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a FORTUNE 500 and S&P 500® health care solutions company listed on the Nasdaq Global Select Market, Henry Schein uses its filings to report financial results, governance changes, and other material events relevant to shareholders and analysts.
Henry Schein’s current reports on Form 8-K offer timely updates on topics such as quarterly and year-to-date financial performance, leadership transitions, and key corporate announcements. For example, recent 8-K filings have furnished press releases reporting financial results for specific quarters and have disclosed changes in senior leadership, including the planned retirement of the Chief Executive Officer from that role and related succession planning.
In addition to 8-Ks, investors typically look to Henry Schein’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. These periodic reports, referenced in company news releases, contain discussions of operations, financial condition, risk factors, and litigation matters, as well as commentary on strategic initiatives and partnerships such as the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P.
Stock Titan enhances these filings with AI-powered summaries that help explain complex disclosures in clear language. Instead of reading entire documents, users can review concise explanations of key points, including segment performance, risk factor highlights, and notable changes in capital allocation or governance. Real-time updates from the EDGAR system mean that new Henry Schein filings, such as 8-Ks reporting financial results or leadership changes, appear promptly on this page.
For those tracking insider activity and executive arrangements, Form 4 and 8-K disclosures relating to departures, appointments, and compensatory arrangements provide additional context on management and board-level decisions. By combining raw filings with AI-generated insights, this page helps investors, researchers, and health care market participants interpret Henry Schein’s regulatory reporting more efficiently.
Faig Carole T reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein director Carole T. Faig received an equity grant from the company. She was awarded 2,577 restricted stock units relating to common stock at a stated price of $0.00 per share as a grant or award.
According to the grant terms, these restricted stock units were issued under Henry Schein's 2023 Non-Employee Director Stock Incentive Plan and generally vest after a 12‑month cliff period, conditioned on her continued service to the company. Following this award, her directly held common stock-related holdings total 8,025 shares.
Henry Schein director Deborah Derby reported an equity award of 2,577 shares of common stock on March 6, 2026. The shares were acquired at a stated price of $0.00 per share as a grant under the company’s 2023 Non-Employee Director Stock Incentive Plan.
According to a footnote, the award consists of restricted stock units that generally vest after a 12-month cliff period, subject to certain exceptions and Ms. Derby’s continued service to Henry Schein. Following this grant, she directly holds a total of 15,093 shares and is also reported as indirect owner, as trustee, of 760 shares held in a trust for her benefit.
DANIEL WILLIAM K reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Daniel William K received an equity award of 2,577 shares of common stock on
BERGMAN STANLEY M reported acquisition or exercise transactions in this Form 4 filing.
Henry Schein Inc. director Stanley M. Bergman reported several stock-related updates involving company common stock. An indirect transaction moved 3,812 shares held via the Bergman Family Trust #2 to a related trust associated with his spouse. Following this, those indirect holdings totaled 379,991 shares held through spouse-related trusts and an LLC.
Bergman also received an award of 2,577 restricted stock units under Henry Schein’s 2023 Non-Employee Director Stock Incentive Plan. These units generally vest after 12 months, conditioned on continued service, bringing his directly held shares to 255,789. The filing further updates his indirect interest in 9,833 equivalent shares held through the Henry Schein 401(k) Savings Plan’s unitized stock fund.
Henry Schein Inc. director Ali Mohamad reported an equity award in the form of common stock. On March 6, 2026, he acquired 2,577 shares at no purchase price through a grant categorized as a grant, award, or other acquisition. The award was made under the company’s 2023 Non-Employee Director Stock Incentive Plan. According to the footnote, these restricted stock units vest after a 12‑month cliff period, and vesting depends on Mohamad continuing to provide services to the company. Following this grant, his directly held common stock position increased to 15,075 shares.
Henry Schein Inc. executive Mark E. Mlotek, EVP and Chief Strategic Officer, reported several transactions in the company’s common stock. On March 4, 2026, he made open-market sales of 4,100 shares at $80.795 per share and 1,825 shares at $80.811 per share.
He also made bona fide gifts of 1,215 shares on March 5, 2026 and 300 shares on March 6, 2026 at a stated price of $0.00 per share, including transfers to family trusts where he serves as trustee. Following these transactions, he directly held 77,539 shares, with additional indirect holdings of 7,416 shares in family trusts and 4,085 equivalent shares through the Henry Schein 401(k) Savings Plan.
Henry Schein Inc. director Philip A. Laskawy sold shares of the company. On March 5, 2026, he completed an open-market sale of 2,844 shares of common stock at a price of $80.36 per share. After this transaction, he directly owned 21,961 shares of Henry Schein common stock.
HSIC submitted a Form 144 notice relating to proposed sales of Common stock. The filing lists two tranches tied to restricted stock vesting: 556 shares dated
Henry Schein Inc. reported that CEO Frederick M. Lowery acquired a sign-on equity-based award of 30,723 shares of common stock in the form of restricted stock units under the company’s 2024 Stock Incentive Plan. The RSUs vest in three equal annual installments, contingent on his continued service.